Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

ProMetic confident IPF drug will outperform current treatments after trial

Wednesday, February 22, 2017 7:22
% of readers think this story is Fact. Add your two cents.

ProMetic Life Sciences Inc’s (TSX:PLI) dosing trial of its idiopathic pulmonary fibrosis treatment PBI-4050 has confirmed early indications of benefit reported in November.

“PBI-4050, either used alone or in Combi-1, demonstrated very promising early indications of efficacy, considering that current drugs approved for IPF only slow (but do not reverse) the decline in lung respiratory function”, said John Moran, Prometic’s chief medical officer. 

“It is also important to note that during our clinical trial, there were no deaths nor did we see any subjects experiencing a decrease in FVC [how much someone can exhale] of 10% or more, contrary to the outcomes in the other IPF trials.”

In addition to demonstrating that the drug was safe and very well tolerated, an endpoint for the trial was to show there was benefit from its prescription either alone or in combination with nintedanib or pirfenidone, the drugs currently prescribed for IPF.

Pierre Laurin, ProMetic’s chief executive, added the results supported the rationale and clinical study design for the Phase 2/3 IPF clinical trial due to start in the second quarter.

“We expect to see PBI-4050, alone or in combination with one of the commercially approved IPF drugs, continue to outperform the current drugs in terms of efficacy, safety and tolerability”.

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.